PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1703821

[Selection of HLA compatible thrombocyte donors using electronic data processing with a newly developed score].

A L König·M Holzer
View original source ↗Export metadata ↓

Abstract

We developed a program for personal computers which selects platelet donors for a given patient according to the following criteria: 1. Anti-CMV-status, 2. ABO-compatibility of various degrees, and 3. HLA-incompatibility. For evaluation of HLA-incompatibility, we created a score which presently provides the following classification: 0 = identical antigen, 5 = same supertypic antigen or blank in the donor, 50 = very frequently cross-reactive antigen, 75 = frequently cross-reactive antigen, very rare antigen or antigen poorly expressed on platelets in the donor, 100 = mismatch.

Explore related subjects

Blood DonorsBlood Group IncompatibilityBlood Grouping and CrossmatchingBlood TransfusionHLA AntigensHumansMicrocomputersPlatelet TransfusionSoftwareEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A L König, M Holzer. 1990. [Selection of HLA compatible thrombocyte donors using electronic data processing with a newly developed score].. https://pubmed.ncbi.nlm.nih.gov/1703821/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

A comparison between one first generation and three second generation anti-HCV ELISAs: an investigation in high- and low-risk subjects in correlation with recombinant immunoblot assay and polymerase chain reaction.

One first generation assay (manufactured by Ortho, test I) and 3 second generation anti-HCV ELISAs (manufactured by Ortho, Abbott, and UBI, tests II-IV) were compared. Sera from 4 different sources were used: (1) intravenous drug-users (IVDUs, n = 50), (2) blood donors (n = 1055), (3) all clinical samples from one day of routine anti-HCV testing (n = 89), (4) hemodialysis patients previously found negative by test I but clinically suspected to have a HCV infection (n = 11). Confirmatory anti-HCV tests were carried out with a second generation recombinant immunoblot assay (RIBA II). In sera positive exclusively by test IV, one antibody consumption test (UBI HCV Neutralization EIA) and one further immunoblot assay (INNO-LIA HCV Ab) were used. PCR for HCV RNA was carried out on all hemodialysis patient sera and in the RIBA II positive blood donor sera. The second generation ELISAs discriminated 11 more positive samples than the first generation test (2 IVDUs, 5 blood donors, 4 clinical samples). The 9 sera from blood donors and clinical samples were all RIBA II positive or indeterminate. The second generation tests thus showed increased sensitivity. The second generation tests also showed increased specificity in that 4 samples that were positive by test I but negative by the second generation tests, were also negative by RIBA II. With few exceptions, all RIBA II-positive and most of the indeterminate samples were positive by the second generation ELISAs. With few exceptions, all the RIBA II-negative samples were negative by the second generation ELISAs. Eleven blood donor sera were positive by test IV exclusively where RIBA II and other supplementary assays were negative. The recently introduced second generation anti-HCV ELISAs were found to have a higher sensitivity than the first generation test. The tests also showed a good concordance with the exception of test IV in the group of blood donor sera.

Blood Donors↗